Nonalcoholic Fatty Liver Disease: Epidemiology, Assessments, and Interventions Entering 2021

Barritt, A. Sidney

doi:10.1016/j.clinthera.2021.01.022

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of hepatic steatosis has substantially increased in the last decade and reached 10–24% worldwide, with a strong association with type II diabetes mellitus (T2DM) and obesity according to several studies, especially in Western societies [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study

Al-Qudimat

Al‐Zoubi

Yassin

et al. 2021

Arab Journal of Urology

View full text Add to dashboard Cite

Objectives : To report the association between testosterone treatment in hypogonadal men with hepatic steatosis, non-alcoholic fatty liver disease and cardiovascular disease (CVD). Methods: A prospective study was conducted to assess the physiological and functional performance of the long-term effects of testosterone undecanoate treatment on hepatic steatosis in 496 hypogonadal men. Two groups were studied, the treatment group (T-group) of 312 patients treated with TU 1000 mg every 12 weeks and followed for 8 years, and an untreated control group (C-group) of 184 patients. We evaluated liver functions and Fatty Liver Index (FLI) according to Mayo Clinic parameters and guidelines. Results: The T-group showed a decrease in the FLI (from a mean [SD] of 83.70 [12.15] to 67.12 [19.21]), bilirubin (from a mean [SD] of 1.69 [4.21] to 1.31 [1.91] mg/dL), triglycerides (from a mean [SD] of 254.87 [92.99] to 213.37 [66.91] mg/dL), and gamma-glutamyl-transferase (from a mean [SD] of 39.45 [11.51] to 29.11 [7.68] U/L) over the duration of the study. Other parameters were also reduced in the T-group such as body mass index (from a mean [SD] of 31.59 [4.51] to 29.50 [3.84] kg/m 2 ) and waist circumference (from a mean [SD] of 107.51 [9.95] to 101.86 [9.28] cm). A total of 25 deaths (7.8%) were recorded in the T-group, among them, 11 (44%) were related to CVD. While in the C-group 28 deaths (15.2%) were recorded and all the reported deaths (100%) were related to CVD. Conclusions: The findings suggest that long-term testosterone therapy in hypogonadal men improves liver function. While, the physiological and functional improvements in the liver may be associated with a decrease in CVD-related mortality. Abbreviations ALT: alanine transaminase; AR: androgen receptor; AST: aspartate transaminase; BMI: body mass index; CVD: cardiovascular disease; FLI: Fatty Liver Index; γ-GT: gamma-glutamyl-transferase; MetS: metabolic syndrome; LDL: low-density lipoprotein; NAFLD: non-alcoholic fatty liver disease; RCT: randomised controlled trial; T2DM: type II diabetes mellitus; TT: total testosterone; TTh: testosterone therapy; TU: testosterone undecanoate; WC: waist circumference

show abstract

Section: Introductionmentioning

confidence: 99%

Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study

Al-Qudimat

Al‐Zoubi

Yassin

et al. 2021

Arab Journal of Urology

View full text Add to dashboard Cite

show abstract

“…NAFLD is a metabolic disorder highly related to obesity and type 2 diabetes mellitus (T2DM) [ 2 ]. This disorder is a complex and progressive disease that can range from the benign condition called simple steatosis (SS) to its development into nonalcoholic steatohepatitis (NASH), an inflammatory-related state that sometimes leads to fibrosis and can evolve into hepatic cirrhosis and hepatocellular carcinoma [ 3 ]. Currently, there are still limited options for NAFLD clinical management in a specific manner due to the lack of noninvasive diagnostic tools and follow-up criteria for populations with a risk of progression [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity

Bertran,

Capellades,

Abelló

et al. 2023

IJMS

View full text Add to dashboard Cite

This study investigated the importance of a metabolomic analysis in a complex disease such as nonalcoholic steatohepatitis (NASH) associated with obesity. Using an untargeted metabolomics technique, we studied blood metabolites in 216 morbidly obese women with liver histological diagnosis. A total of 172 patients were diagnosed with nonalcoholic fatty liver disease (NAFLD), and 44 were diagnosed with normal liver (NL). Patients with NAFLD were classified into simple steatosis (n = 66) and NASH (n = 106) categories. A comparative analysis of metabolites levels between NASH and NL demonstrated significant differences in lipid metabolites and derivatives, mainly from the phospholipid group. In NASH, there were increased levels of several phosphatidylinositols and phosphatidylethanolamines, as well as isolated metabolites such as diacylglycerol 34:1, lyso-phosphatidylethanolamine 20:3 and sphingomyelin 38:1. By contrast, there were decreased levels of acylcarnitines, sphingomyelins and linoleic acid. These findings may facilitate identification studies of the main pathogenic metabolic pathways related to NASH and may also have a possible applicability in a panel of metabolites to be used as biomarkers in future algorithms of the disease diagnosis and its follow-up. Further confirmatory studies in groups with different ages and sexes are necessary.

show abstract

Nonalcoholic Fatty Liver Disease: Epidemiology, Assessments, and Interventions Entering 2021

Cited by 2 publications

References 10 publications

Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study

Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study

LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity

Contact Info

Product

Resources

About